The Role of Cardiac Magnetic Resonance in Patients with Dilated Cardiomiopathy
By:
References
- 1. Marthe AJ. Becker, Jan H. Cornel, Peter M. van de Ven, Albert C. van Rossum, Cornelis P. Allaart, Tjeerd Germans. The Prognostic Value of Late Gadolinium-Enhanced Cardiac Magnetic Resonance Imaging in Nonischemic Dilated Cardiomyopathy. JACC Cardiovasc Imaging. 2018 Sep;11(9):1274-1284. doi: 10.1016/j.jcmg.2018.03.006.10.1016/j.jcmg.2018.03.006
- 2. Patel, AR Kramer CM. Role of Cardiac Magnetic Resonance in the Diagnosis and Prognosis of Non-Ischemic Cardiomyopathy. JACC Cardiovasc Imaging. 2017 October;10(10 Pt A):1180–1193. doi:10.1016/j.jcmg.2017.08.005.10.1016/j.jcmg.2017.08.005
- 3. Bogaert J, Dymarkowski S, Taylor AM et al. Clinical Cardiac MRI. second edition. Leuven:Springer; 2012.10.1007/978-3-642-23035-6
- 4. Myerson SG, Francis J, Neubauer S. Carrdiovascular Magnetic Resonance. Chapter 6. Ischaemic heart disease. Myocardial viability; 2010. p. 162-163.10.1093/med/9780199549573.003.06
- 5. Pettersen SE, Khanji MY, Plein S, Lancelloti P, Bucciarelli-Duci C. European Association of Cardiovascular Imaging expedet consensus paper: a comprehensive review of cardiovascular magnetic resonance normal values of cardiac chamber size and aortic root in adults and recommendations for grading severity. European Heart Journal – Cardiovascular Imaging. 2019 December; 20(12):1321-1331. https://doi.org/10.1093/ehjci/jez232.10.1093/ehjci/jez232
- 6. Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342:1077-84.10.1056/NEJM200004133421502
- 7. Disertori M, Quintarelli S, Mazzola S, Favalli V, Narula N, Arbustini E. The need to modify patient selection to improve the benefits of implantable cardioverterdefibrillator for primary prevention of sudden death in nonischaemic dilated cardiomyopathy. Europace. 2013;15:1693-701.10.1093/europace/eut228
- 8. Nakahara S, Tung R, Ramirez RJ, et al. Characterization of the arrhythmogenic substrate in ischemic and nonischemic cardiomyopathy implications for catheter ablation of hemodynamically unstable ventricular tachycardia. J Am Coll Cardiol. 2010;55:2355-65.10.1016/j.jacc.2010.01.041
- 9. Hsia HH, Callans DJ, Marchlinski FE. Characterization of endocardial electrophysiological substrate in patients with nonischemic cardiomyopathy and monomorphic ventricular tachycardia. Circulation. 2003;108:704-10.10.1161/01.CIR.0000083725.72693.EA
- 10. Gorgels AP, Gijsbers C, de Vreede- Swagemakers J, Lousberg A, Wellens HJ. Out-ofhospital cardiac arrest: the relevance of heart failure. The Maastricht Circulatory Arrest Registry. Eur Heart J. 2003;24:1204-9.10.1016/S0195-668X(03)00191-X
- 11. Stecker EC, Vickers C, Waltz J, et al. Populationbased analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study. J Am Coll Cardiol. 2006;47:1161-6.10.1016/j.jacc.2005.11.045
- 12. Ponikowski P, Voors AA, Anker SD, et al. 2016ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force forthe diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129-200.10.1093/eurheartj/ehw128
- 13. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Eur Heart J. 2015;36:2793-867.10.1093/eurheartj/ehv316
- 14. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.10.1056/NEJMoa013474
- 15. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-37.10.1056/NEJMoa043399
- 16. Kober L, Thune JJ, Nielsen JC, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375:1221-30.10.1056/NEJMoa1608029
- 17. Nijveldt R, Beek AM, Hirsch A, et al. Functional recovery after acute myocardial infarction: comparison between angiography, electrocardiography, and cardiovascular magnetic resonance measures of microvascular injury. J Am Coll Cardiol. 2008;52:181-9.10.1016/j.jacc.2008.04.006
- 18. Nijveldt R, van der Vleuten PA, Hirsch A, et al. Early electrocardiographic findings and MR imaging-verified microvascular injury and myocardial infarct size. J Am Coll Cardiol Img. 2009;2:1187-94.10.1016/j.jcmg.2009.06.008
- 19. Epstein AE, DiMarco JP, Ellenbogen KA, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2013;61:e6-75.10.1016/j.jacc.2012.11.007
- 20. Ponikowski P, Voors AA, Anker SD, et al. 2016ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129-200.10.1093/eurheartj/ehw128
- 21. Leyva F, Taylor RJ, Foley PW, et al. Left ventricular midwall fibrosis as a predictor of mortality and morbidity after cardiac resynchronization therapy in patients with nonischemic cardiomyopathy. Journal of the American College of Cardiology. 2012;60:1659-67. [PubMed: 23021326]10.1016/j.jacc.2012.05.054
- 22. Kawel N, Nacif M, Zavodni A, Jones J, Liu S, Sibley CT, Bluemke DA. T1 mapping of the myocardium: intra-individual assessment of the effect of field strength, cardiac cycle and variation by myocardial region. J Cardiovasc Magn Reson. 2012;14:27.10.1186/1532-429X-14-27
- 23. Philip Haaf, Pankaj Garg, Daniel R. Messroghli, David A. Broadbent, John P. Greenwood, Sven Plein. Cardiac T1 Mapping and Extracellular Volume (ECV) in clinical practice: a comprehensive review. Journal of Cardiovascular Magnetic Resonance. 2016;18:89 DOI 10.1186/s12968-016-0308-4.10.1186/s12968-016-0308-4
- 24. Sado DM, Flett AS, Banypersad SM, White SK, Maestrini V, Quarta G, Lachmann RH, Murphy E, Mehta A, Hughes DA, McKenna WJ, Taylor AM, Hausenloy DJ, Hawkins PN, Elliott PM, Moon JC. Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart. 2012;98:1436-41.10.1136/heartjnl-2012-302346
- 25. aus dem Siepen F, Buss SJ, Messroghli D, Andre F, Lossnitzer D, Seitz S, Keller M, Schnabel PA, Giannitsis E, Korosoglou G, Katus HA, Steen H. T1 mapping in dilated cardiomyopathy with cardiac magnetic resonance: quantification of diffuse myocardial fibrosis and comparison with endomyocardial biopsy. Eur Heart J Cardiovasc Imaging. 2015;16:210-6.10.1093/ehjci/jeu183
- 26. h-Ici DO, Jeuthe S, Al-Wakeel N, Berger F, Kuehne T, Kozerke S, Messroghli DR. T1 mapping in ischaemic heart disease. Eur Heart J Cardiovasc Imag. 2014;15:597-602.10.1093/ehjci/jeu024
- 27. Ferreira VM, Holloway CJ, Piechnik SK, Karamitsos TD, Neubauer S. Is it really fat? Ask a T1- map. Eur Heart J Cardiovasc Imaging. 2013;14:1060.10.1093/ehjci/jet095
Language: English
Page range: 26 - 29
Submitted on: Nov 6, 2020
Accepted on: May 3, 2021
Published on: Aug 5, 2021
Published by: Lucian Blaga University of Sibiu
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2021 Georgiana Bălţat, Ioan Maniţiu, Monica Yepez Benavides, Cornel Ioan Bitea, Denisa Dincă, Gabriela Eminovici, Minodora Teodoru, published by Lucian Blaga University of Sibiu
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.